Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020

NEXT STORY
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe
PREV STORY
CRISPR Technology Market to Grow by 20.91% in 2020, Accelerated by the Outbreak of COVID-19 – Industry Projections to 2030
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News

Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology

author_avatar
NASDAQ Market News

Vanderbilt LifeFlight Named National Program of the Year by Leading Trade Organization

author_avatar
NASDAQ Market News